Researchers Submit Patent Application, "Protein Antigens And Uses Thereof", for Approval (USPTO 20230241207).
In: Vaccine Weekly, 2023-08-25, S. 181-181
serialPeriodical
Zugriff:
Since whole tumor cells are isolated from the autologous patient, the cells may include patient-specific tumor antigens as well as shared tumor antigens. The shared tissue restricted tumor antigens are ideally immunogenic proteins with selective expression in tumors across many individuals and are commonly delivered to patients as synthetic peptides or recombinant proteins. The method of claim 52, wherein the peptide comprises at least two different viral protein epitope sequences, wherein the gene encoding each of the at least two different viral protein epitope sequences is BALF5 of EBV, E6 of EPV-16, or a combination thereof. Such vaccines contain either shared tissue restricted tumor antigens or a mixture of shared and patient-specific antigens in the form of whole tumor cell preparations. [Extracted from the article]
Copyright of Vaccine Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Researchers Submit Patent Application, "Protein Antigens And Uses Thereof", for Approval (USPTO 20230241207).
|
---|---|
Zeitschrift: | Vaccine Weekly, 2023-08-25, S. 181-181 |
Veröffentlichung: | 2023 |
Medientyp: | serialPeriodical |
ISSN: | 1074-2921 (print) |
Schlagwort: |
|
Sonstiges: |
|